Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.67 |
| ▸ | HTR2A | P28223 | 7/20 | 0.67 |
| ▸ | HTR2B | P41595 | 5/20 | 0.67 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL329949 | 1.00 | HTR2C (0.67) | HTR2CHTR2AHTR2BMEN1CYP3A4 | |
| SCHEMBL329626 | 1.00 | HTR2C (0.67) | HTR2CHTR2AHTR2BMEN1CYP3A4 | |
| SCHEMBL31159134 | 1.00 | HTR2C (0.67) | HTR2CHTR2AHTR2BMEN1CYP3A4 | |
| Hydrochloric Acid SCHEMBL2259898 | 0.98 | HTR2C (0.65) | HTR2CHTR2AHTR2BMEN1CYP3A4 | |
| Hydrochloric Acid SCHEMBL38653867 | 0.98 | HTR2C (0.65) | HTR2CHTR2AHTR2BMEN1CYP3A4 | |
| Hydrochloric Acid SCHEMBL38652787 | 0.98 | HTR2C (0.65) | HTR2CHTR2AHTR2BMEN1CYP3A4 | |
| SCHEMBL164205 | 0.80 | HTR2C (1.00) | HTR2CHTR2AHTR2BTAAR1ADRB1 | |
| Bromide SCHEMBL174576 | 0.79 | HTR2C (0.96) | HTR2CHTR2AHTR2BTAAR1ADRB1 | |
| Water SCHEMBL16465743 | 0.79 | HTR2C (0.96) | HTR2CHTR2AHTR2BTAAR1ADRB1 | |
| Iodide SCHEMBL174548 | 0.79 | HTR2C (0.96) | HTR2CHTR2AHTR2BTAAR1ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS AG (CH) | 2025-05-29 | — | — | US | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| EP-4540240-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | Monte Rosa Therapeutics AG (CH) | 2025-04-23 | — | — | EP | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| EP-4400497-A1 | 3CLPRO PROTEASE INHIBITOR | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2024-07-17 | — | — | EP | disclosed |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| EP-3628045-B1 | COMPOUNDS | UNIV SHEFFIELD (GB) | 2024-07-03 | — | — | EP | disclosed |
| WO-2023244815-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20040220222-A1 | Malonamide derivatives | F. HOFFMAN-LA ROCHE AG, A SWISS COMPANY (CH) | 2004-11-04 | — | — | US | disclosed |
| EP-1448547-A1 | PYRIDINE DERIVATIVES AS NMDA RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-25 | — | — | EP | disclosed |
| WO-2004069826-A1 | MALONAMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-19 | — | — | WO | disclosed |
| US-20030119870-A1 | Pyridine substituted isoquinoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2003-06-26 | — | — | US | disclosed |
| WO-2003040128-A1 | PYRIDINE DERIVATIVES AS NMDA RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-15 | — | — | WO | disclosed |
| US-5789595-A | ANTICOAGULANTS | TERUMO KABUSHIKI KAISHA (JP) | 1998-08-04 | — | — | US | disclosed |
| EP-0790247-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE AND MEDICINAL PREPARATION CONTAINING THE SAME | TERUMO KABUSHIKI KAISHA (JP) | 1997-08-20 | — | — | EP | disclosed |
| EP-0230871-B1 | HALOACYL 1-SUBSTITUTED-1,2,3,4-TETRAHYDROISOQUINOLINES AS HERBICIDE ANTIDOTES | Monsanto Company (US) | 1993-09-22 | — | — | EP | disclosed |
| US-4755218-A | Reducing acetochlor injury to corn by applying with antidote | MONSANTO COMPANY (US) | 1988-07-05 | — | — | US | disclosed |
| EP-0230871-A2 | Haloacyl 1-substituted-1,2,3,4-tetrahydroisoquinolines as herbicide antidotes | Monsanto Company (US) | 1987-08-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220222-A1 | Malonamide derivatives | BACE1, BACE2, APP | HTR2C 3177/4885HTR2A 3569/4885HTR2B 2143/4885 |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | HTR2C 4185/4885HTR2A 3630/4885HTR2B 4201/4885 |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | HTR2C 3544/4885HTR2A 3868/4885HTR2B 4767/4885 |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | HTR2C 1015/4885HTR2A 1865/4885HTR2B 813/4885 |
| US-20030119870-A1 | Pyridine substituted isoquinoline derivatives | GRIN1, GRIN2C, GRIN2A | HTR2C 247/4885HTR2A 329/4885HTR2B 370/4885 |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | PSMA1, CSNK1G1, CSNK1A1 | HTR2C 4347/4885HTR2A 3841/4885HTR2B 4230/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | HTR2C 1015/4885HTR2A 1865/4885HTR2B 813/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | HTR2C 1015/4885HTR2A 1865/4885HTR2B 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.